Home › Funds › Bratton Capital Management, L.P. › AQST

Bratton Capital Management, L.P. position in AQST

AQUESTIVE THERAPEUTICS INC · Health Care

Bratton Capital Management, L.P. reported holding 9,810,958 shares of AQST (AQUESTIVE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$45.4M, representing 100.00% of its reported portfolio and ranking #1 among its reported holdings. Bratton Capital Management, L.P. has disclosed AQST holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)9.81M sh
Reported value held$45.42M
Portfolio Weight100.00%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Bratton Capital Management, L.P.'s AQST position evolved

Bratton Capital Management, L.P. first disclosed a stake in AQST in Q3 2023 at 9,810,958 shares (US$1.50B). Across 13 filings, Bratton Capital Management, L.P. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 9,810,958 shares valued at US$45.4M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 9.81M $1.50B New
Q4 2023 9.81M $19.82M Hold
Q1 2024 9.81M $41.79M Hold
Q2 2024 9.81M $25.51M Hold
Q3 2024 9.81M $48.86M Hold
Q4 2024 9.81M $34.93M Hold
Q1 2025 9.81M $28.45M Hold
Q2 2025 9.81M $32.47M Hold
Q3 2025 9.81M $54.84M Hold
Q4 2025 9.81M $63.38M Hold
Q1 2026 9.81M $40.72M Hold
Q2 2026 9.81M $40.81M Hold
Q3 2026 9.81M $45.42M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AQST and 13F data

AQST (AQUESTIVE THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in AQST — the largest reported positions include Samsara BioCapital, LLC (US$10.4M), Propel Bio Management, LLC (US$8.6M), Blue Owl Capital Holdings LP (US$6.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AQST

All AQST fund holders →

FAQ

How long has Bratton Capital Management, L.P. held AQST?

Bratton Capital Management, L.P. has disclosed AQST holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Bratton Capital Management, L.P.'s current position in AQST?

As of Q3 2026, Bratton Capital Management, L.P. holds 9.81M shares of AQST (AQUESTIVE THERAPEUTICS INC), valued at $45.42M, representing 100.00% of its reported portfolio and ranking #1.

Has Bratton Capital Management, L.P. been buying or selling AQST?

In the latest 13F filing (Q3 2026), Bratton Capital Management, L.P. held unchanged its position in AQST.

Which other funds hold AQST?

Other major institutional holders of AQST include Samsara BioCapital, LLC, Propel Bio Management, LLC, Blue Owl Capital Holdings LP, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.